This segment focuses on the research, development, and commercialization of novel therapies for central nervous system (CNS) disorders. Research and development activities include clinical trials for various conditions such as major depressive disorder, Alzheimer's disease agitation, narcolepsy, and fibromyalgia. The company utilizes small molecule and potentially other therapeutic approaches. Patient impact is addressed by providing innovative treatments for conditions with limited treatment options. Axsome aims to establish a strong market position through its innovative pipeline and strategic partnerships. Future opportunities include expanding the product portfolio and geographic reach. Regulatory and clinical aspects are crucial, with a focus on obtaining FDA approvals and ensuring patient safety. Partnerships with institutions like Duke University support research efforts.